Navigation Links
MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
Date:9/19/2007

FT. LAUDERDALE, Fla., Sept. 19 /PRNewswire-FirstCall/ -- MAKO Surgical Corp. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock.

All of the offered shares will be sold by MAKO Surgical Corp. The number of shares to be offered and the price range of the offering have not yet been determined. The Company intends to apply to have its common stock approved for quotation on the NASDAQ Global Market under the symbol "MAKO."

J.P. Morgan Securities Inc. and Morgan Stanley & Co. Incorporated will act as joint bookrunners for the offering and Cowen and Company, LLC and Wachovia Capital Markets, LLC will act as co-lead managers. The offering will be made only by means of a prospectus. Copies of the preliminary prospectus for the offering, when available, may be obtained from: J.P. Morgan Securities Inc., National Statement Processing, Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245 or by phone at (718) 242-8002; or Morgan Stanley & Co. Incorporated's prospectus department at 180 Varick, New York, NY 10014, by telephone at (866) 718-1649 or by emailing prospectus@morganstanley.com.

About MAKO Surgical Corp.

MAKO Surgical Corp. is a medical device company that markets its advanced robotic solution and implants for minimally invasive orthopedic knee procedures. MAKO's Haptic Guidance System(TM) includes an interactive haptic robotics platform that utilizes tactile-guided robotics and patient-specific visualization to prepare the knee joint for the insertion and alignment of resurfacing implants through a keyhole incision. This FDA-cleared surgeon- interactive haptic robotic system allows surgeons to provide an innovative tissue-sparing bone resurfacing therapy called MAKOplasty(TM) to a large, yet underserved patient-specific population suffering from early to mid-stage osteoarthritic knee disease. As of September 18, 2007, 80 MAKOplasty procedures have been performed since commercial introduction in June 2006. MAKO has an intellectual property portfolio of more than two hundred licensed or owned patent applications relating to the areas of computer assisted surgery, haptics, robotics, and implants.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.


'/>"/>
SOURCE MAKO Surgical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Evaluation of RNA isolated from human tissues: quality control for surgical and postmortem samples
2. Surgical products company wins Governors Business Plan Contest
3. Vector Surgical hopes to turn frustration into faster surgeries
4. Metavante Corp. will continue M&A activity
5. Lucigen Corp. enters global licensing agreement
6. CIO Leadership Series: Jane Durment, Marcus Corp.
7. Brady Corp. acquires Korean counterpart
8. Brady Corp. raises $137 million in public offering
9. Symphony Corp. and CareEvolution to partner
10. RedPrairie Corp. introduces new supply chain software
11. California investors acquire RedPrairie Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... , ... AMRI, a global contract research, development and manufacturing ... and quality of life, will now be offering its impurity solutions as a ... requirements for all new drug products, including the finalization of ICH M7 earlier ...
(Date:10/11/2017)... ... ... is a basic first aid supply for any work environment, but most personal eye wash ... if a dangerous substance enters both eyes? It’s one less decision, and likely quicker response ... piece. , “Whether its dirt and debris, or an acid or alkali, getting anything in ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
(Date:10/10/2017)... SAN DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... website as part of its corporate rebranding initiative announced today. The bold new ... broaden its reach, as the company moves into a significant growth period. , It ...
Breaking Biology Technology:
(Date:6/30/2017)... , June 30, 2017 Today, ... developer and supplier of face and eye tracking ... Featured Product provider program. "Artificial ... innovative way to monitor a driver,s attentiveness levels ... from being able to detect fatigue and prevent ...
(Date:5/16/2017)... 2017   Bridge Patient Portal , an ... MD EMR Systems , an electronic medical record ... have established a partnership to build an interface ... GE Centricity™ products, including Centricity Practice Solution (CPS), ... These new integrations will allow healthcare delivery networks ...
(Date:4/17/2017)... April 17, 2017 NXT-ID, Inc. (NASDAQ: ... the filing of its 2016 Annual Report on Form 10-K on ... ... is available in the Investor Relations section of the Company,s website ... SEC,s website at http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):